Skip to main content
SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD logo

SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000078 ISIN · CNE000000X95 LEI · 300300J4GCOV7CYQTB51 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,616 across all filing types
Latest filing 2024-12-30 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000078

About SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD

https://www.neptunusbio.com

Shenzhen Neptunus Bioengineering Co., Ltd. is a comprehensive healthcare enterprise focused on the research, development, manufacturing, and distribution of pharmaceutical products. The company operates across the entire industry value chain, including the production of chemical drugs, biological preparations, and traditional Chinese medicines. Its portfolio extends to medical devices and health supplements. A significant component of its operations involves a large-scale pharmaceutical distribution network and a nationwide retail pharmacy chain. The company emphasizes innovation in biotechnology and maintains modern production facilities to support its diverse product lines. By integrating R&D with a robust logistics and retail infrastructure, it provides a wide range of healthcare solutions to medical institutions and consumers.

Recent filings

Filing Released Lang Actions
北京德恒（深圳）律师事务所关于深圳市海王生物股份有限公司2024年第四次临时股东大会的法律意见
Regulatory Filings Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the legality of the convening, procedures, attendance, proposals, voting, and results of the 2024 fourth extraordinary general meeting of shareholders of Shenzhen Haiwang Bioengineering Co., Ltd. It details the meeting's notice, attendance, voting methods, and results, and confirms compliance with relevant laws and company articles. The document is not the meeting materials themselves, nor is it a direct announcement of voting results or a proxy solicitation. It is a legal opinion verifying the legitimacy of the meeting and its procedures, which is typically filed as a Regulatory Filing (RNS) since it does not fit into other specific categories like AGM Information, Declaration of Voting Results, or Proxy Solicitation. The document length (6536 characters) and content confirm it is a standalone legal opinion report, not a brief announcement or a full report like an Annual Report or Interim Report.
2024-12-30 Chinese
独立董事关于公开征集表决权的公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement by an independent director of Shenzhen Haier Bioengineering Co., Ltd. regarding the public solicitation of voting rights for the company's 2024 fourth extraordinary general meeting of shareholders. It details the solicitation process, the proposals to be voted on, the voting intentions of the independent director, and the procedures for shareholders to authorize voting rights. The document does not contain financial statements or results but is a formal announcement related to shareholder voting rights and proxy solicitation. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it concerns the solicitation and delegation of voting rights for shareholder proposals at a general meeting.
2024-12-16 Chinese
关于2024年第四次临时股东大会增加临时提案暨股东大会补充通知的公告
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed announcement regarding the convening of the 2024 fourth extraordinary general meeting of shareholders of Shenzhen Haier Bioengineering Co., Ltd. It includes information about the meeting date, agenda items, voting procedures, and proxy authorization. It does not contain financial statements or detailed financial analysis but rather focuses on the logistics and agenda of a shareholder meeting. This fits the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA) or a Proxy Solicitation & Information Statement (PSI). However, since it is about the notice and supplementary information for the shareholder meeting including proposals and voting instructions, it aligns best with Proxy Solicitation & Information Statement (PSI). The document length is 4630 characters, which is sufficient for a detailed proxy statement but not a full financial report. Therefore, the classification is PSI with high confidence.
2024-12-16 Chinese
监事会关于第九届监事会第十七次会议相关事项的审核意见
Audit Report / Information Classification · 85% confidence The document is a supervisory board's audit opinion on a specific meeting matter related to the controlling shareholder's commitment extension. It is a formal statement from the supervisory board, not a full audit report or annual report. It does not contain financial statements or detailed financial data. It is also not a regulatory filing or announcement of a report publication. The content fits best under Audit Report / Information (AR) as it is an audit opinion on a corporate governance matter related to compliance and shareholder interests. FY 2024
2024-12-16 Chinese
第九届监事会第十七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolution from the Supervisory Board meeting of Shenzhen Haiwang Bioengineering Co., Ltd. It details the meeting date, attendance, agenda items, voting results, and references related announcements. It does not contain financial statements or detailed financial data, nor is it a report or presentation. It is a regulatory announcement about board-level decisions, specifically from the Supervisory Board, which falls under Board/Management Information category. The document length is short and it is not an announcement of a report publication but a direct disclosure of board meeting resolutions.
2024-12-16 Chinese
关于公司控股股东避免同业竞争承诺延期的公告
Board/Management Information Classification · 95% confidence The document is an announcement from Shenzhen Haiwang Bioengineering Co., Ltd. regarding the extension of a commitment by its controlling shareholder to avoid competition within the same industry. It details the original commitment, previous extension, reasons for the current extension, and the approval process by the board and supervisory committee. The content focuses on governance and compliance matters related to shareholder commitments and corporate governance practices rather than financial results, audit, or capital changes. There is no financial data or report attached, nor is it a transcript or presentation. The document is a formal announcement about management and shareholder commitments and related board approvals. Therefore, it fits best under Board/Management Information (MANG).
2024-12-16 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.